XIENCE
XIENCE is a medical device with 14 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 10 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
UnknownTrial Status & Enrollment
100.0%
10 of 10 finished
0.0%
0 ended early
0
trials recruiting
14
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug-coated Stents and the Xience Drug-eluting Stent System in Patients With Acute Coronary Syndrome and High Bleeding Risk Using Optical Coherence Tomography
A Randomized Comparison of Long-Term Healing Between Biodegradable- Versus Durable-Polymer Everolimus Eluting Stents in STEMI
Absorb IV Randomized Controlled Trial
A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II
ABSORB III Randomized Controlled Trial (RCT)
Clinical Trials (14)
A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug-coated Stents and the Xience Drug-eluting Stent System in Patients With Acute Coronary Syndrome and High Bleeding Risk Using Optical Coherence Tomography
A Randomized Comparison of Long-Term Healing Between Biodegradable- Versus Durable-Polymer Everolimus Eluting Stents in STEMI
Absorb IV Randomized Controlled Trial
A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II
ABSORB III Randomized Controlled Trial (RCT)
XIENCE 28 USA Study
XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
XIENCE 28 Global Study
Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent
A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Efficacy of Angiolite Stent vs a Second-generation Drug-eluting Stent Xience for Percutaneous Coronary Intervention
Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial
ABSORB Bioresorbable Scaffold vs. Xience Metallic Stent for Prevention of Restenosis in Patients at High Risk of Restenosis
Evaluation of Everolimus-Eluting Stents (The K-XIENCE Registry)
All 14 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 14